Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 68

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling

Li, Guo-fu, Wang, Kun, Chen, Rui, Zhao, Hao-ru, Yang, Jin, Zheng, Qing-shan·2012·Acta Pharmacologica Sinica
DOI 10.1038/aps.2012.103
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/aps.2012.103

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 59

  1. Cruickshank JM . Beta-blockers and heart failure. Indian Heart J 2010; 62: 101–10.
  2. de Groote P, Ennezat PV, Mouquet F . Bisoprolol in the treatment of chronic heart failure. Vasc Health Risk Manag 2007; 3: 431–9.
  3. McGavin JK, Keating GM . Bisoprolol: a review of its use in chronic heart failure. Drugs 2002; 62: 2677–96. · DOI
  4. Papadopulos DP, Papademetriou V . Low-dose fixed combination of bisoprolol /hydrochlorothiazide as first line for hypertension: a review of the rationale and clinical evidence. Angiology 2009; 60: 601–7. · DOI
  5. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9–13. · DOI · Paper page
  6. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671–8. · DOI · Paper page
  7. Damman K, Voors AA, Hillege HL, Navis G, Lechat P, van Veldhuisen DJ, et al. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail 2010; 12: 974–82. · DOI
  8. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004; 25: 1341–62. · DOI · Paper page
  9. Brophy KM, Scarlett-Ferguson H, Webber KS . Clinical drug therapy for Canadian practice. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2010.
  10. Kirch W, Rose I, Demers HG, Leopold G, Pabst J, Ohnhaus EE . Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clin Pharmacokinet 1987; 13: 110–7. · DOI
  11. Nestorov I . Whole body pharmacokinetic models. Clin Pharmacokinet 2003; 42: 883–908. · DOI · Paper page
  12. Rowland M, Balant L, Peck C . Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29–30, 2002). AAPS PharmSci 2004; 6: E6. · DOI
  13. Edginton AN, Theil FP, Schmitt W, Willmann S . Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 2008; 4: 1143–52. · DOI
  14. Rowland M, Peck C, Tucker G . Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011; 51: 45–73. · DOI · Paper page
  15. Le Jeunne C, Poirier JM, Cheymol G, Ertzbischoff O, Engel F, Hugues FC . Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers. Eur J Clin Pharmacol 1991; 41: 171–4. · DOI
  16. Leopold G, Pabst J, Ungethüm W, Bühring KU . Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist. J Clin Pharmacol 1986; 26: 616–21. · DOI
  17. Ding L, Zhou X, Guo X, Song Q, He J, Xu G . LC-ESI-MS method for the determination of bisoprolol in human plasma. J Pharm Biomed Anal 2007; 44: 520–5. · DOI
  18. Jones HM, Gardner IB, Watson KJ . Modelling and PBPK simulation in drug discovery. AAPS J 2009; 11: 155–66. · DOI
  19. Jones HM, Dickins M, Youdim K, Gosset JR, Attkins NJ, Hay TL, et al. Application of PBPK modelling in drug discovery and development at Pfizer. Xenobiotica 2012; 42: 94–106. · DOI · Paper page
  20. Poirier A, Funk C, Scherrmann JM, Lavé T . Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. Mol Pharm 2009; 6: 1716–33. · DOI
  21. Rodgers T, Rowland M . Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 2006; 95: 1238–57. · DOI
  22. Parrott N, Davies B, Hoffmann G, Koerner A, Lave T, Prinssen E, et al. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. Clin Pharmacokinet 2011; 50: 613–23. · DOI
  23. Hinderling PH . Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev 1997; 49: 279–95. · DOI
  24. Yang J, Jamei M, Yeo KR, Rostami-Hodjegan A, Tucker GT . Misuse of the well-stirred model of hepatic drug clearance. Drug Metab Dispos 2007; 35: 501–2. · DOI
  25. Gabrielsson J, Weiner D . Pharmacokinetic and pharmacodynamic data analysis: concept and applications, 4th ed. Stockholm: Swedish Pharmaceutical Press; 2006.
  26. Lin JH . Species similarities and differences in pharmacokinetics. Drug Metab Dispos 1995; 22: 1008–21. · DOI · Paper page
  27. Lin JH . Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 1998; 26: 1202–12.
  28. Huang W, Lee SL, Yu LX . Mechanistic approaches to predicting oral drug absorption. AAPS J 2009; 11: 217–24. · DOI
  29. Li GF, Yang J, Zhang XY, Zhao HR . Physiologically based gastrointestinal models for the prediction of oral drug absorption. Chin J Clin Pharmacol Ther 2010; 15: 656–62. Chinese.
  30. Kuentz M, Nick S, Parrott N, Röthlisberger D . A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur J Pharm Sci 2006; 27: 91–9. · DOI
  31. Reddy MB, Connor A, Brennan BJ, Morcos PN, Zhou A, McLawhon P, et al. Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible. Biopharm Drug Dispos 2011; 32: 261–75. · DOI
  32. Davies B, Morris T . Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093–5. · DOI
  33. Zhang X, Lionberger RA, Davit BM, Yu LX . Utility of physiologically based absorption modeling in implementing quality by design in drug development. AAPS J 2011; 13: 59–71. · DOI
  34. Ogiu N, Nakamura Y, Ijiri I, Hiraiwa K, Ogiu T . A statistical analysis of the internal organ weights of normal Japanese people. Health Phys 1997; 72: 368–83. · DOI
  35. Mannhold R, Poda GI, Ostermann C, Tetko IV . Calculation of molecular lipophilicity: State-of-the-art and comparison of log P methods on more than 96 000 compounds. J Pharm Sci 2008; 98: 861–93. · DOI
  36. De Buck SS, Sinha VK, Fenu LA, Gilissen RA, Mackie CE, et al. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab Dispos 2007; 35: 649–59. · DOI
  37. Lee AC, Crippen GM . Predicting pKa. J Chem Inf Model 2009; 49: 2013–33. · DOI
  38. Rodgers T, Leahy D, Rowland M . Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat. J Pharm Sci 2005; 94: 1237–48. · DOI
  39. Gomeni R . PHARM — an interactive graphic program for individual and population pharmacokinetic parameter estimation. Comput Biol Med 1984; 14: 25–34. · DOI
  40. Abuasal BS, Bolger MB, Walker DK, Kaddoumi A . In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate. Mol Pharm 2012; 9: 492–504. · DOI
  41. Tubic M, Wagner D, Spahn-Langguth H, Bolger MB, Langguth P . In silico modeling of nonlinear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. Pharm Res 2006; 23: 1712–20. · DOI
  42. Peters SA . Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles. Clin Pharmacokinet 2008; 47: 245–59. · DOI
  43. Peters SA, Hultin L . Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat. J Pharmacokinet Pharmacodyn 2008; 35: 1–30. · DOI
  44. Parrott N, Lave T . Applications of physiologically based absorption models in drug discovery and development. Mol Pharm 2008; 5: 760–75. · DOI
  45. Fruehauf H, Goetze O, Steingoetter A, Kwiatek M, Boesiger P, Thumshirn M, et al. Intersubject and intrasubject variability of gastric volumes in response to isocaloric liquid meals in functional dyspepsia and health. Neurogastroenterol Motil 2007; 19: 553–61. · DOI
  46. Brophy CM, Moore JG, Christian PE, Egger MJ, Taylor AT . Variability of gastric emptying measurements in man employing standardized radiolabeled meals. Dig Dis Sci 1986; 31: 799–806. · DOI
  47. Petring OU, Flachs H . Inter- and intrasubject variability of gastric emptying in healthy volunteers measured by scintigraphy and paracetamol absorption. Br J Clin Pharmacol 1990; 29: 703–8. · DOI
  48. Poulin P, Theil FP . Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharma Sci 2002; 91: 129–56. · DOI · Paper page
  49. De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA . Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 2007; 35: 1766–80. · DOI · Paper page
  50. Yamazaki S, Skaptason J, Romero D, Vekich S, Jones HM, Tan W, et al. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one compartment model. Drug Metab Dispos 2011; 39: 383–93. · DOI
  51. Yang X, Gandhi YA, Duignan DB, Morris ME . Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure-pharmacokinetic relationships. AAPS J 2009; 11: 511–25. · DOI
  52. Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 2007; 34: 401–31. · DOI
  53. Howell BA, Chauhan A . A physiologically based pharmacokinetic (PBPK) model for predicting the efficacy of drug overdose treatment with liposomes in man. J Pharm Sci 2010; 99: 3601–19. · DOI
  54. Tahara K, Kagawa Y, Takaai M, Taguchi M, Hashimoto Y . Directional transcellular transport of bisoprolol in P-glycoprotein-expressed LLC-GA5-COL150 cells, but not in renal epithelial LLC-PK1 cells. Drug Metab Pharmacokinet 2008; 23: 340–6. · DOI
  55. Thomas S . Clinical relevance of predictive physiologically based pharmacokinetic methods. Expert Opin Drug Dis 2008; 3: 725–32. · DOI
  56. Huang SM, Temple R, Xiao S, Zhang L, Lesko LJ . When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective. Clin Pharmacol Ther 2009; 86: 475–9. · DOI
  57. Nestorov I . Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics. Toxicol Lett 2001; 120: 411–20. · DOI
  58. Thompson CM, Johns DO, Sonawane B, Barton HA, Hattis D, Tardif R, et al. Database for physiologically based pharmacokinetic (PBPK) modeling: physiological data for healthy and health-impaired elderly. J Toxicol Environ Health B Crit Rev 2009; 12: 1–24. · DOI
  59. Hudachek SF, Gustafson DL . Customized in silico population mimics actual population in docetaxel population pharmacokinetic analysis. J Pharm Sci 2011; 100: 1156–66. · DOI

Cited by

Metadata

Authors
Li, G.-F., Wang, K., Chen, R., Zhao, H.-R., Yang, J., & Zheng, Q.-S.
Venue
Acta Pharmacologica Sinica
Publisher
Springer Science and Business Media LLC
Published
2012-10-22
Volume
33
Issue
11
Pages
1359-1371
ISSN
  • 1671-4083
  • 1745-7254
DOI
10.1038/aps.2012.103
Cited by
68
References
6
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.